摘要
目的探讨CYP2C9基因多态性对某院冠心病伴房颤患者药物抗凝治疗及消化道不良反应的影响,为临床提供合理用药证据。方法选择2018年1月至2020年1月某三甲医院33例冠心病伴房颤的患者为研究对象,检测其基因类型,观察药物抗凝治疗效果、联合用药情况以及是否有消化道症状的出现。结果不同CYP2C9基因代谢类型的患者完全缓解、部分缓解、疗效不佳的占比差异有统计学意义(P=0.025),不同用药组的疗效构成比差异亦有统计学意义(P=0.004)。不同代谢类型、不同联合方案组的消化道症状患者构成比差异均有统计学意义。结论CYP2C9基因突变类型对冠心病伴房颤患者的药物抗凝治疗效果、消化道症状的出现会产生影响。
OBJECTIVE To investigate the effect of CYP2C9 gene polymorphism on drug anticoagulant therapy and gastrointestinal adverse reactions in patients with coronary heart disease complicated with atrial fibrillation in a hospital,provide clinical evidence for rational drug use.METHODS From January 2018 to January 2020,33 patients in the top three hospitals who were diagnosed with coronary heart disease complicated with atrial fibrillation were enrolled in the study.Detect its genotype,the effect of drug anticoagulant treatment,the combination of drug use and the occurrence of gastrointestinal symptoms were observed.RESULTS The proportions of complete remission,partial remission and poor curative effect in patients with different CYP2C9 gene metabolism types were significantly different(P=0.025),There was also a statistically significant difference in the composition ratio of curative effects among different drug groups(P=0.004).There were statistically significant difference in the composition ratio of patients with gastrointestinal symptoms in different metabolic types and different combination regimen groups.CONCLUSION The type of CYP2C9 gene mutation has an impact on the effect of drug anticoagulant therapy and the appearance of gastrointestinal symptoms in patients with coronary heart disease complicated with atrial fibrillation.
作者
林明瑞
江清菊
刘华容
LIN Ming-rui;JIANG Qing-ju;LIU Hua-rong(Department of Pharmacy,Provincial Clinical Medical College Fujian Medical University,Fuzhou 350001,China)
出处
《海峡药学》
2022年第12期128-130,共3页
Strait Pharmaceutical Journal
